Jazz Pharmaceuticals announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz’s continued focus on advancing treatment for rare and difficult-to-treat sleep disorders with new clinical research and real-world evidence evaluating Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia.
“People living with narcolepsy and idiopathic hypersomnia, while profoundly affected by symptoms, face challenges in diagnosis and navigating treatment considerations,” said Jessa Alexander, Ph.D., neuroscience therapeutic area head, global medical and scientific affairs of Jazz Pharmaceuticals. “The research Jazz is unveiling at SLEEP 2026 is rooted in the day-to-day realities of patients, reflecting our commitment to conduct studies that mirror real-world experiences and treatment paradigms. This comprehensive approach allows our research to inform care decisions and address the full complexity of these conditions, spanning the 24-hour burden of sleep inertia, daytime symptoms and sleep as well as the meaningful implications of reducing long-term sodium intake.”
Key highlights at SLEEP 2026 include:
- An oral presentation featuring a post-hoc analysis of the DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) study, examining objective and subjective sleep inertia in participants with narcolepsy (type 1 and type 2) taking Xywav.
- Two poster presentations reporting post-hoc analyses of the DUET study exploring outcomes for idiopathic hypersomnia participants taking Xywav treatment, with one evaluating objective and patient-reported sleep inertia and the other exploring outcomes of Xywav treatment when stratified by individual ideal sleep duration.
- A poster presentation showcasing changes in hypersomnolence among participants with narcolepsy taking Xywav dosages >9 grams per night, compared to 9 grams at baseline, in the DUET study. The current recommended dosage of Xywav for adults with narcolepsy is 6-9 grams per night.
- Six poster presentations featuring comprehensive findings from the real-world, longitudinal, mixed-methods LYRICAL study, examining the treatment experience and dosing patterns of U.S. adults with idiopathic hypersomnia or narcolepsy taking Xywav.
- Two poster presentations detailing the development of conceptual disease models of the symptoms and impact of narcolepsy type 1 and narcolepsy type 2, respectively, from the patient perspective to better understand the most bothersome symptoms and meaningful impacts.
Source: PR Newswire
